Evidence map›Paper›PMID 34265150›Full record

ReviewChembiochem : a European journal of chemical biology2021

Hidden in Plain Sight: Natural Products of Commensal Microbiota as an Environmental Selection Pressure for the Rise of New Variants of SARS-CoV-2.

Jovan Dragelj, Maria Andrea Mroginski, Kourosh H Ebrahimi

Erratum issuedOpen access · bronzeAbstract readReview
In one paragraph

Review in Chembiochem : a European journal of chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. A lipidomic view of SARS-CoV-2.Bioscience reports · 2021
    Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Jovan DrageljInstitute of Chemistry, Technische Universität Berlin, Straße des 17. Juni 135, 10623, Berlin, Germany.
Maria Andrea MroginskiInstitute of Chemistry, Technische Universität Berlin, Straße des 17. Juni 135, 10623, Berlin, Germany.
Kourosh H EbrahimiChemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, Oxford, OX1 3TA, UK.
Technische Universität Berlin · DEUniversity of Oxford · GB

Funding

COST (European Cooperation in Science and Technology) Action CA15133 ECOST-STSM-Request-CA15133-44200CRUK Oxford Developmental Fund CRUKDF-0221-KHECRUK Oxford Developmental Fund CRUKDF - 0221 - KHEDeutsche Forschungsgemeinschaft (DFG, German Research Foundation) EXC 2008-390540038-UniSysCatDeutsche Forschungsgemeinschaft (DFG, German Research Foundation) EXC 2008 - 390540038 - UniSysCatEuropean Molecular Biology Organization (EMBO) EMBO ALTF 157-2015
6 · The paper itself

Abstract

Since the emergence of SARS-CoV-2, little attention has been paid to the interplay between the interaction of virus and commensal microbiota. Here, we used molecular docking and dynamics simulations to study the interaction of some of the known metabolites and natural products (NPs) produced by commensal microbiota with the receptor binding domain (RBD) of the spike glycoprotein of SARS-CoV-2. The results predict that NPs of commensal microbiota such as bile acids and non-ribosomal peptides (NRPs), of which some are siderophores, bind to the wild-type RBD and interfere with its binding to the ACE2 receptor. N501Y mutation, which is present in many of the emerging variants of the virus, abolishes the predicted binding pocket of bile acids and NRPs. Based on these findings, available experimental data showing that bile acids reduce the binding affinity of wild-type RBD to the ACE2 receptor, and the data suggesting that the respiratory tract microbiota affect viral infection we put forward the following proposal: mutations such as N501Y enable the RBD to bind to the ACE2 receptor more effectively in the presence of NPs produced by the respiratory tract bacteria thereby, increasing the infectivity rate of the virus. We hope our data stimulate future works to better understand the interactions of NPs produced by commensal microbiota with respiratory viruses like SARS-CoV-2.

Indexed as

Biological ProductsMicrobiotaAnimalsBacteriaComputer SimulationCOVID-19Genetic VariationHumansProtein Interaction Domains and MotifsReceptors, VirusSARS-CoV-2Biological ProductsReceptors, Virusbile acidscommensal microbiotanatural productsNRPsSARS-CoV-2

Identifiers

PMID34265150
PMCPMC8427076
OpenAlexW3177884970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.